Why Compounded Semaglutide Stings: Injection-Site Reactions and pH

A brief sting when injecting compounded semaglutide or tirzepatide can often be linked to formulation and technique: the preservative, the solution's pH and buffer, how much liquid each dose takes, and whether it's injected cold. Mild redness, itching, or bruising also shows up with brand-name GLP-1s. Spreading redness, warmth, pus, or fever is different and points to possible infection, which needs prompt medical attention.

What brand labels report about injection-site reactions

Brand prescribing information gives the clearest numbers for how often these drugs cause skin reactions where they're injected. Compounded products have no equivalent data, because they aren't studied in approval trials.

Source: Zepbound prescribing information (rev. 08/2026); Wegovy prescribing information (rev. 06/2026). Trial rates are not directly comparable across different drugs and studies.

So some local reaction is a known effect of the drugs themselves. What compounded products add is variability: different preservatives, concentrations, and pH from one pharmacy to the next, and sometimes from one refill to the next.

Formulation factors that can affect how a shot feels

Preservative: benzyl alcohol and others

Multi-dose vials need a preservative. Many compounded GLP-1s are made with, or mixed with, bacteriostatic water. One FDA-labeled bacteriostatic water product contains 0.9% (9 mg/mL) or 1.1% (11 mg/mL) benzyl alcohol, and its label carries the warning "NOT FOR USE IN NEONATES" (Hospira bacteriostatic water label).

Benzyl alcohol isn't unique to compounding. Zepbound's multi-dose vial and KwikPen list benzyl alcohol (5.4 mg per dose), glycerin, and phenol as excipients, while Zepbound's single-dose pen and vial do not list benzyl alcohol (Zepbound PI). The Wegovy FlexTouch pen contains phenol; Wegovy's single-dose injection lists disodium phosphate, sodium chloride, and water (Wegovy PI).

How painful are preservatives? A 2019 literature review of subcutaneous injection pain reported that pain was comparable between phenol and benzyl alcohol in the studies it reviewed, and that "m-cresol seems to be more painful than benzyl alcohol and phenol" (Usach et al., Adv Ther 2019). The review was funded by Sandoz, and two of its authors were Sandoz employees.

pH and buffer

Wegovy has a pH of about 7.4, and Zepbound's label gives a pH of 6.5 to 7.5, close to the body's own (Wegovy PI; Zepbound PI). The Hospira bacteriostatic water label lists a pH of 5.7, with a range of 4.5 to 7.0. The final pH of a compounded GLP-1 depends on its full recipe, not just the diluent, and pharmacies rarely print it on the label.

The Usach review says a pH close to physiological is recommended "to minimize pain, irritation, and tissue damage," and it discusses buffers too. It cites a study in which 10 mM citrate caused more immediate pain than 4.4 mM histidine, though the difference was gone at two minutes, and it cautions that the evidence on buffers is not very solid (Usach et al.).

Volume per dose

The same review reports that roughly 1.5 mL is generally accepted as a maximum for a subcutaneous injection, and that volumes of about 0.5 to 0.8 mL are expected not to substantially increase pain (Usach et al.). Concentration matters here. The more dilute the vial, the more liquid each dose takes.

Temperature

Cold injections can sting more. The Usach review notes a recommendation that refrigerated injectable biopharmaceuticals sit at room temperature for about 30 minutes before injection. Whether that is appropriate for your compounded product depends on the pharmacy's storage instructions, so ask before changing anything.

Technique habits worth reviewing with your pharmacist

• Rotate sites. The Ozempic label lists the abdomen, thigh, and upper arm as injection areas and tells prescribers to instruct patients to use a different injection site each week when injecting in the same body region (Ozempic PI).
• Use a new sterile needle and syringe every time. FDA advises this for compounded GLP-1 vials. It also recommends discarding multi-dose vials within 28 days of first use because of the "increased risk of contamination after 28 days" (FDA). Follow your pharmacy's beyond-use date if it is shorter.
• Let the alcohol swab dry before inserting the needle, so you don't push wet alcohol into the skin.
• Needle size. Evidence that thinner needles hurt less is mixed; one study reported painful insertions falling from 63% to 31% across 23 to 32 gauge, while others found no difference within narrower ranges (Usach et al.). Ask what syringe your pharmacy supplies and why.
• Injection speed. The same review concluded that injection speed "seems to have no impact on injection-related pain" across the rates studied.

Irritation vs. infection: the red flags

Ordinary irritation is usually small, appears around the time of the injection, and fades. Infection behaves differently. MedlinePlus lists cellulitis symptoms that include redness or inflammation that "gets bigger as the infection spreads," skin that is tight, glossy, and warm, pain or tenderness, and fever with chills. It advises contacting a provider right away if you have symptoms of cellulitis (MedlinePlus).

Sources: Zepbound and Wegovy prescribing information; MedlinePlus cellulitis overview. This table is a general guide, not a diagnosis.

A product quality problem can also show up as an injection-site reaction, and a patient can't tell the cause by looking. That is one more reason to keep the vial and report the problem rather than troubleshooting on your own.

If you suspect a problem with the vial

1. Stop using the vial and keep it in its labeled box, separate from other medication.
2. Photograph the injection site daily, and photograph the vial and label, including the lot number and beyond-use date.
3. Contact your prescriber about the symptoms, and the dispensing pharmacy about the product.
4. Report it to FDA through the MedWatch online form. FDA notes that state-licensed pharmacies that aren't outsourcing facilities aren't required to report adverse events to it, so patient reports matter.

Scenario guidance

It only started after a refill

Compare the old and new labels. Look for a different concentration, a different pharmacy, or new listed ingredients. Bring both labels to your pharmacist.

It stings every time, but there's no redness afterward

Ask the pharmacy what preservative and diluent it uses and whether a preservative-free or different formulation is available. Your prescriber may also discuss an FDA-approved product.

A lump or redness appears and grows over a day or two

Treat this as possible infection, not irritation. Contact your prescriber that day.

Questions to ask your pharmacy or prescriber

• What preservative and diluent are in my product, and what is the concentration?
• Has the formula or concentration changed since my last fill?
• What volume is my dose, and is there a more concentrated option?
• Should I let the dose warm before injecting, given your storage instructions?
• What syringe and needle do you recommend for this product?
• What reaction should prompt me to stop and call you?

Where this guide stops

This article explains general factors linked to injection discomfort. It cannot tell you why a particular injection hurts or whether a specific product is sterile. It is not a substitute for examination by a clinician. Any sign of infection or a serious allergic reaction needs medical care, not home troubleshooting.

Compare available care options

If ongoing reactions have you reconsidering your product or pharmacy, verify the prescriber's and pharmacy's credentials and terms yourself. A listing is not a recommendation or a prescription.

Disclosure: we may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legitimacy, or value.

Sources

1. FDA: Compounding Laws and Policies
2. Zepbound prescribing information, Eli Lilly (rev. 08/2026)
3. Wegovy prescribing information, Novo Nordisk (rev. 06/2026)
4. Bacteriostatic Water for Injection, USP (Hospira) label
5. Usach I, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996
6. Ozempic prescribing information, Novo Nordisk (rev. 05/2026)
7. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of Oct. 1, 2026)
8. MedlinePlus: Cellulitis
9. FDA MedWatch online reporting form

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.